Takara Bio USA Holdings completed the acquisition of Curio Bioscience.

Takara Bio-backed Takar Bio USA Holdings, a life sciences company, completed the acquisition of Curio Bioscience, a biotechnology company, advancing high-precision tools for the life sciences industry. Financial terms were not disclosed. “Curio Bioscience is dedicated to creating innovative approaches that map the entire transcriptome with unparalleled sensitivity and resolution. Combining Curio’s technology with Takara Bio’s vast NGS and single-cell tool set will provide customers with industry-leading solutions for their spatial biology needs,” Stephen Fodor, Curio Bioscience co-founder and CEO.